ET-AF8 SPAF I31 WASPO32 Sequence Allocation generation concealment Low Low Low
ET-AF8 SPAF I31 WASPO32 Sequence Allocation generation concealment Low Low Low Low VEGF121 Protein MedChemExpress Unclear Low Low Unclear Low Low Unclear Unclear Low Low Low Low Low Low Low Unclear Unclear Unclear Low Low Low Unclear Low Unclear Low Low Unclear Low Tryptophan Hydroxylase 1/TPH-1 Protein site Blinding of Blinding of Incomplete participants/personnel outcomes outcome information Low Higher Low High Low Low High Low Low Low High Higher High Low Low High Unclear Unclear Unclear Low Low Low Low Low Low Low Low High Low Low Low Unclear Unclear Unclear Unclear Unclear Low Low Low Low Unclear Unclear Low Unclear Unclear Low Low Higher Selective Intention-to- Overall reporting treat analysis Low Low High Low Low Low Low Low Unclear Low Low Unclear Low Low Low Unclear Yes Yes Unclear Yes Yes Yes Yes Yes Yes Yes Yes Unclear Yes Yes Yes Yes Low Unclear Unclear Unclear Low Low Low Low Low Low Low Higher Low Low Low UnclearNote: Authors did not report the amount of events corresponding to a principal end point.ASA + C was linked with a larger risk than all other therapy options. The risk of ICH on ASA was higher than on placebo. Lastly, the danger of ICH on rivaroxaban was larger than that of dabigatran 110 mg and edoxaban LD.Ranking and inconsistencyThe ranking distributions in Figure 3 represent the proportions of simulations in which every single therapy was ranked in each and every position (from finest to worst) based on its effectiveness against ischemic stroke and main bleeding. For ischemic stroke, dabigatran 150 mg was shown to become essentially the most effectiveoption in 84 of simulations, followed by rivaroxaban (9 ), apixaban (five ), and edoxaban HD (2 ). None of the other treatment options was one of the most successful selection in any of your simulations. For major bleeding, edoxaban LD was one of the most successful alternative in 72 of simulations, followed by placebo (28 ). None on the other treatment options was one of the most effective choice in any in the simulations. While the risk of significant bleeding on any OAC is greater than that on placebo, information on key bleeding although on placebo are scarce (ie, pretty few events occurring in smaller research), resulting in weak evidence for this outcome on placebo. Via inspectionClinical Pharmacology: Advances and Applications 2016:submit your manuscript | www.dovepressDovepressTawfik et alDovepressTable two Study characteristicsStudy Therapy Sample Follow-up Major size (n) (years) finish points three,772 3,782 three,335 3,371 336 336 169 170 9,088 9,025 2,808 two,791 485 488 191 187 404 378 7,035 7,034 7,036 426 445 104 91 three.28 3.24 1.25 1.25 1.08 1.13 two.16 two.09 1.69 1.65 1.1 1.1 two.7 2.7 1.27 1.27 2.07 1.89 two.19 2.24 two.21 2.1 two.1 1.64 1.48 two two two 1.57 1.58 1.three 1.29 1 1 OD, S, SE, TIA, MB, withdrawal S, SE, MB, non-MB (clinically relevant) IS, SE S, SE CVD, OD Disabling S, ICH, AE Non-lacunar IS, SE, ICH, fatal bleeding VD, non-fatal S, non-fatal MI, SE S, SE S, SE, MB S or SE S, SE S, TIA, SE All Ischemic Myocardial All round Important Intracranial strokes stroke infarction mortality bleeding hemorrhage (n) (n) (n) (n) (n) (n) 235 343 90 42 NR NR 5 4 149 155 35 93 32 ten 9 six 64 73 236 233 235 17 18 NR NR 152 103 134 149# 161 23 42 0#ACTIVE-A18 ACTIVE-WASA + C ASA ASA + C Warfarin ASA PlaceboS, SE, MI, VD 296 408 S, SE, MI, VD one hundred 59 15 16 9 10 199 250 49 105 44 21 9 7 88 90 281 360 317 CVD, IS, TIA 21 20 four 3 171 122 186 184# 221 24 42 0#90 115 36 23 NR NR 4 4 90 102 24 28 15 15 NR NR NR NR 133 169 141 NR NR NR NR 98 97 75 101 126 7 12 NR NR825 841 159 158 NR NR 14 17 603 669 111 140 108 107 eight ten 102 99 773 737 839 10 9 7 9 446 438 487 582 632 39 50 2.